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Sm_mmary The detection of bone marrow involvement might be of prognostic value and may influence
therapeutic decisions in small cell lung cancer. By unilateral bone marrow aspiration and biopsy, evidence of
bone marrow metastases is seen in 15-30% of patients with this disease. Since magnetic resonance imaging of
the lower body and immunostaining with monoclonal antibodies have recently been shown to be very
sensitive detection methods, we investigated the value of these two techniques in detecting bone marrow
involvement in 35 consecutive patients with small cell lung cancer. The results were compared to those
obtained with conventional cytohistological analysis. In all cases when cytology and or bone marrow biopsy
were positive, monoclonal antibodies immunostaining and magnetic resonance imaging also detected
malignant cells. Furthermore, evidence of bone marrow involvement was shown with magnetic resonance
imaging and/or immunostaining in 10 of 26 cases (38%) where routine procedures were unable to detect
malignant cells. In one of these 26 patients. magnetic resonance imaging and immunostaining provided the
only evidence of metastatic disease. These data suggest that the rate of bone marrow metastases is
underestimated by routine procedures. Further investigation is needed to determine whether or not these new
non-invasive methods have prognostic value or affect therapeutic choices in small cell lung carcinoma.
Bone marrow (BM) involvement is common in patients with
small cell lung cancer (SCLC) although it is still not clear
whether it is of prognostic value in this disease. In one study
(Ihde et al., 1981), BM metastases had little prognostic
value, since the difference in survival rates (8 months versus
10 for patients with no BM involvement detected) was not
statistically significant. In other series, BM involvement
predicted a significantly lower median duration of response
and median survival time (Hirsch & Hansen, 1980).
From a therapeutic point of view, BM involvement is
known to increase haematological toxicity of conventional
treatment (Hirsch & Hansen, 1980). Furthermore, undetec-
table BM tumour cells may be the cause of some of the
relapses observed after intensive chemotherapy followed by
autologous BM transplantation in SCLC (Spitzer et al.,
1986; Humblet et al., 1987). Thus, knowledge of BM
involvement at the time of diagnosis in SCLC is of great
importance.
Routine detection of BM metastases in SCLC usually
consists of unilateral posterior iliac crest aspiration and
biopsy. With this procedure, BM involvement is found in
15-30% of patients (Hirsch & Hansen, 1980; Ihde &
Hansen, 1981; Hansen et al., 1978; Hirsch et al., 1977; Anner
& Drewinko, 1977; Choi & Carey, 1976; Holoye et al.,
1977). However, BM infiltration is detected in 35-66% of
patients at necropsy (Kristjansen et al., 1986; Ihde et al.,
1979). Furthermore, among SCLC patients with negative
BM biopsy, BM involvement is seen in 8-11% with the use
of in vitro semi-solid culture techniques (Carney et al., 1980;
Pollard et al., 1981; Neumann et al., 1984; Canon et al.,
1988), 22% with discontinuous gradient sedimentation
method (Hunter et al., 1987) and 50% with BM aspirates
immunostained with monoclonal antibodies (MoAB) (Stahel
et al., 1985). Thus, routine cytological and histological
examination of the BM is likely to underestimate greatly the
rate of BM metastases in SCLC.
Magnetic resonance imaging (MRI) has recently been
shown to be a very sensitive test for the detection of BM
involvement in patients with lymphoma (Shields et al.. 1987)
Correspondence: V. Trillet.
Received 15 November 1988. and accepted in revised form 7
February 1989.
and neuroblastoma (Couanet & Jeoffray, 1988). We investi-
gated the use of both MRI and immunological analysis with
MoAB for BM staging in patients diagnosed with SCLC,
and compared the results of these two new methods with
conventional cytohistological methods.
Patients and lmthods
Patients
From 15 Apnrl 1987 to 15 August 1988, 35 previously
untreated patients with histologically proven SCLC were
referred to our institution. There were 33 men and 2 women,
with a median age of 61 years. Initial staging included
routine blood tests, fibreoptic bronchoscopy+biopsies, CT
scan of the thorax, abdominal ultrasonography and/or CT
scan, brain C( scan and radionuclide bone scan (RBS)+BM
staging (see below). With all these procedures, 27 out of 35
(77%) patients were considered to have metastatic disease at
the time of diagnosis.
Cvtological and histological examination of the BM
In all patients, unilateral posterior iliac crest aspiration and
biopsy were performed before treatment. Several smears were
made from the aspirate and cytologic examination was done
after Wright coloration.
The biopsies were performed according to the method
described by Jamshidi & Swaim (1971) with a median length
of 2.5cm and touch imprints made from each biopsy. After
decalcification, pathological slices were prepared with
Haematoxylin and Eosin staining before light microscopic
examination.
MoAB immunostaining
In 33 of 35 patients, 2-3 ml of aspirated marrow were mixed
with heparin and mononuclear BM cells were immediately
obtained by Ficoll separation for immunological analysis.
Two MoABs of the immunoglobulin (Ig) G isotype (UJ 13 A
kindly provided by J. Kemshead, 11.14 kindly provided by
J.C. Laurent, SANOFI) recognise antigens expressed by cells
of neuroectodermal origin (Favrot et al., 1986; Rosier &
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Laurent, 1987), and CD45 of the IgM isotype (kindly
provided by G. Janossy) recognises the panleucocyte antigen
(Kemshead et al., 1983; Maritaz et al., 1988).
Double immunofluorescence immunostaining Two samples
(1.3 x 106 cells in suspension in 100 p1 phosphate buffer
saline (PBS) with 0.1% NaN3) were incubated with the two
MoABs (one for each sample) in combination with CD45.
After 10 min at 24"C, samples were washed once in PBS and
incubated with TRITC anti-mouse IgM specific and FITC
anti-mouse IgG specific (Southern Biotechnology Associates)
for Omin at 24 C. Samples were then washed twice, main-
tained in PBS-glycerol and analysed in a fluorescent Zeiss
microscope with a 40: 1 objective, a 490 nm excitation filter
and a K 530 barrier filter. Cells are considered malignant
when positive with at least one of the 2 anti-neuroectodermal
antigens MoABs and negative with the CD45.
Alkaline phosphatase immunostaining BM cells in sus-
pension at 6 x I0O ml 1 in PBS are cytocentrifuged into glass
(100p1 per smear at 70g for 5min in a Shandon cytospin).
Immunochemical staining is performed using an indirect 3-
stage immunoenzymatic procedure with alkaline phosphatase
(Dakopatts, Copenhagen, Denmark). Briefly, six air-dnred
slides are fixed for 3min with acetone at 4-C, incubated for
60mmn with MoABs (3 for UJ 13A and 3 for 11.14) then for
30min with enzyme-conjugated rabbit anti-mouse Ig (Dako-
patts) and for 30 min with enzyme-conjugated swine anti-
rabbit Ig (Dakopatts). Washes are done with Tris buffer.
The final step consists of a 15 min incubation with Naphtol-
As-Mx phosphate. dimethylformamide, levamisole and fast
red (Sigma Co., St Louis, USA). Slides are counterstained
with Haematoxylin, mounted permanently with glycerin and
evaluated under an optical microscope. Negative controls
without MoAB and positive controls with MoABs recognis-
ing class I antigen on normal BM cells are included in each
test.
The limit of detection of those two immunological
methods is of one malignant cell in 105 normal mononuclear
BM cells if 3 x 106 cells are analysed in double immuno-
fluorescence and six smears in alkaline phosphatase (Maritaz
et al., 1988; Combaret et al., 1989).
Magnetic resonance imaging
All patients were studied with a 0.5T superconductive
magnet (Magni Scan 5000 Thomson CGR) using a body coil
and a large field of view (500mm). Ten millimetre thick
contiguous slices of the pelvic bony structures including
femoral heads, upper extremities of the femurs, pelvic bones
(iliac. sacrum), and two or three lower lumbar vertebral
bodies were obtained in the coronal plane in order to include
from anterior to posterior all the BM of these structures.
A Tl-weighted spin echo sequence was performed using a
TR of 500ms and a TE of 26ms. With this sequence, 16
contiguous slices are obtained within 10min of positioning
the patient within the coil. With this sequence, BM in
normal adults is seen as homogeneous areas of high signal
intensity. MR images were analysed by one operator.
MR examinations were considered to be positive or nega-
tive depending on the presence or absence of focal areas of
low signal intensity within an area of normal signal intensity
corresponding to marrow fat, as already described in malig-
nant lymphoma (Shields et al., 1987) and in SCLC (Trillet et
al.. 1988).
Radionuclide bone scan (RBS)
RBS was performed in 32 out of the 35 patients, 2 h after a
bolus intravenous injection of 9 MBq per kg hydroxymethyl-
diphosphonate labelled with 99Tc. Investigators were asked
to provide an unambiguous result (positive or negative) and
were blinded to the findings of the four other methods.
Results
In eight patients, cytological examination of the BM was
positive (Table I). BM biopsy was positive in only five out of
these eight patients. In one case (no. 23). BM biopsy was
positive with negative cytology. Thus. BM involvement was
detected with cytological and,or histological examination in
9/35 (26%) cases: MRI was positive in all nine cases. BM
involvement appearing as focal areas of low signal intensity
within the normal signal intensity of marrow fat (Figures la
and 2); this correlated with strongly positive immunostaining
in all eight cases where it was performed with the percentage
of malignant cells ranging from 10-4 to 0.6.
Of the 26 patients with negative conventional cyto-
histology, MRI and/or MoABs detected BM metastases in
10 (38%) cases: three had both positive MRI and immuno-
staining, six had positive MRI only, and one had positive
immunostaining alone. MRI and immunostaining were nega-
tive in 16 of the 26 patients and in one case (no. 10) where
immunostaining was not done, MRI was negative.
Five (14%) patients had extensive disease but no evidence
of BM involvement using conventional and specialised
techniques.
MoABs UJ 13 A and 11-14 stained more than 95% SCLC
tumour samples with very homogeneous staining of malig-
nant cells. Table II shows the concordance between immuno-
fluorescence and alkaline phosphatase immunostairing. A
limitation to the use of MoABs against SCLC on BM
samples is their reactivity with very few normal cells of the
NK lineage. The use of double immunofluorescence analysis
permits one to accurately distinguish between those few
normal cells (stained with UJ 13A, 11-14 and the anti-pan-
leucocyte MoAB) and malignant cells negative with the anti-
Table I Results of MoAB immunostaining and MRI findings com-
pared to routine procedures
Stage
ED
ED
ED
ED
ED
ED
ED
ED
ED
LD
ED
ED
ED
ED
ED
ED
ED
ED
ED
ED
ED
ED
ED
ED
LD
LD
LD
LD
LD
LD
LD
ED
ED
ED
LD
Patient
2
22
26
29
3
24
15
23
25
11
31
12
17
16
35
20
32
14
4
5
6
7
8
18
21
28
9
30
33
34
13
19
27
10
BM
biopsy MoAB
+ ND
+ +
+ +
+ +
+ +
+
_
+
+
+ +
+
+
ND -
ND -
RBS
+
ND
+
+
ND
+
+
ND
+*
+*
+*
- ND
ND. not done; +, positive; -. negative; LD. limited disease; ED.
extensive disease; *, RBS was positive in areas where MRI was not
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Table H Results of MoAB immunostaining
IF AP
+ +
ND +
+ +
+ +
+ ND
ND
ND
ND
ND
Percentage of malignant
cells quantifed bi the
immuaostaining
10-4
6x 10-1
2x10 1
2x 10-1
10-,
10-2
10-3
10- 2
o-5
10-
10- 3
ND. not done; +, positive; -, negative; IF, double immuno-
fluorescence: AP, alkaline phosphatase.
panleucocyte MoAB. The morphological control used with
the alkaline phosphatase method also provides objective
criteria for malignancy.
RBS (Table I) provided evidence of cortical bone involve-
ment in 14 cases, 11 of which also had positive MRI. The
remaining patients (nos. 13, 19 and 27) with negative MRI
were shown to have bone metastases of the sternum or the
dorsal spinal column, locations not studied by MRI. Five
patients had positive MRI and normal RBS. Bone CT scan
was performed in two of them and no abnormality was seen
at the location of the MRI abnormal areas (Figure lb).
In one (no. 2) of the 27 patients with extensive disease,
BM was the only metastatic site and BM invasion was
detectable by cytohistological examination as well as by
MoAB immunostaining and MRI. Nine out of the 10
patients with positive MRI and/or MoAB examination of
the BM and a negative routine examination were shown to
have at least one other metastatic site at diagnosis. Thus,
only one patient (no. 25) was shifted from the 'limited
disease' group to the 'extensive disease' group by including
these two new methods in the initial staging.
Discussion
In our series, it appears that analysis of one BM aspirate
was positive in three cases where biopsy was negative,
whereas there was only one example of false negative
cytology compared to histological examination of the BM.
These results are consistent with the conclusions of Hirsch
and co-workers (Hirsch et al., 1977) on a group of 203
SCLC patients where BM aspiration was shown to be more
effective than BM biopsy in detecting BM metastases in
SCLC. On the contrary, Lawrence (Lawrence et al., 1984)
claimed that histological examination of the BM was super-
ior. when long enough BM specimens were obtained, that is,
with the use of the Jamshidi needle instead of the shorter
Radner needle used by the Danish group. But in most
instances, his patients underwent a second and even a third
biopsy 'through the same skin incision from a location of a
few millimeters lateral to the first'.
This is in accordance with previous reports on many
neoplastic diseases (Brunning et al., 1975) including SCLC
(Hirsch et al., 1979) which demonstrate that the number of
positive BM aspirates and biopsies increases with bilateral
examination of the BM. The rate of detection of BM
involvement is clearly related to the total amount of BM
tissue analysed and this is thought to result from the focal
pattern of BM invasion by malignant cells (Lawrence et al.,
1984). However, invasive procedures such as bilateral iliac
crest trephines are often considered aggressive and investi-
gators have been encouraged to develop new non-aggressive
methods of detection.
Immunological analysis is a highly sensitive method and
allows detection of malignant cells in roughly 50% SCLC
patients using MoABs directed against SCLC cells surface
antigens like SMI (Stahel et al., 1985) or MOC (Postmus,
personal communication). Here, the concentration of malig-
nant cells by Ficoll separation, the analysis of a very large
number of cells and the use of objective criteria of malig-
nancy such as morphologic control (alkaline phosphatase
method) and double membrane immunostaining with two
different markers (double immunofluorescence method)
improves the level of detection to 10-5 cells and allows the
identification of malignant cells with cytological lymphoid-
like features. MoAB immunostaining allows an estimate of
the proportion of malignant cells. In the four cases where
MoAB immunostaining was positive while routine pro-
cedures were negative, the contamination in the aspirate was
low (less than or equal to 10-3). In one of our patients,
MoAB immunostaining was the only positive test.
Of the nine patients with positive MRI and negative
cytology and biopsy, three showed positive immunostaining
of the BM and, in the remaining six patients. the signals
obtained with MRI were very similar to those observed in
cytologically positive BM patients, and similar to those
described as typical features of BM involvement leukaemias,
lymphomas, neuroblastomas and SCLC. Furthermore. pat-
terns of positivity (multiple focal areas of hyposignals) tend
to confirm the focal nature of BM involvement and may
explain the insensitivity of methods based on the examin-
ation of a single aspiration or biopsy site, including immuno-
logical analysis. MRI has the advantage of being painless.
being able to scan a wide part of the body and being
particularly sensitive to focal involvement. There is a need
for the confirmation of malignant BM invasion in the sites
of MRJ hyposigiials, in patients with normal BM aspiration
and normal biopsy in one iliac crest.
RBS is a highly sensitive but very non-specific test in
SCLC (Levenson et al., 1981). In our study, all RBS-positive
patients also had a positive MRI, except for three cases
where bone metastases were detected outside the MRI field
of view. In contrast, in five patients with positive MRI. RBS
was negative. MRI focal areas of low intensity are located in
the fat tissue, that is, in BM itself (Porter et al.. 1986). In
contrast, RBS abnormalities reflect cortical bone involve-
ment. Therefore, no comparison can be made between these
two methods in terms of sensitivity and specificity. However,
the lack of bone metastases detected with RBS and CT bone
scan in MRI-positive areas might reflect different patterns of
BM and cortical bone involvement in SCLC. According to
our results with MRI, metastatic spread in the BM could be
an earlier event than cortical bone involvement with SCLC.
This sequence of bone invasion is concordant with the
figures shown in our study: the rate of BM metastases
detected with MRI (50%) is greater than the usual rate of
bone metastases (30-35% in most series) (Ihde & Hansen.
1981).
The necessity of BM sampling in SCLC has recently been
questioned by some authors (Campling et al.. 1986). Accord-
ing to our preliminary results, routine cyto-histological
examination of the BM might fail to detect BM involvement
in 38% of patients with SCLC and BM could be a very
frequent site of detectable malignant cells in SCLC using
MRI and MoAB immunostaining. In our opinion, in a
disease where the presence and number of metastatic sites is
known to be an important prognostic factor, this finding
strongly supports routine examination of the BM with these
two complementary and non-aggressive methods. Further-
more, if future results confirm the superiority of cytological
and immunological examination of BM aspiration compared
to biopsy, the latter aggressive method could possibly be
abandoned.
The fact that some patients might be diagnosed as having
metastatic instead of limited disease could be of a prognostic
importance since it could improve the selection of truly
'limited stage' patients to be treated with a 'curative intent'.
Patient
2
22
26
29
3
24
15
23
25
11
31
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However, compared to the series of Carney et al. (1988)
where 45% of the patients were restaged after MRI exanin-
ation of the BM, we found only one patient with apparently
'limited disease' where MRI and/or MoAB immunostaining
resulted in the re-classification in the 'extensive disease'
category. This is possibly due both to different patient
selection (since 23% of our patients were in the 'limited
disease' group versus 60% in Carney's study) and to better
routine evaluation of the BM (26% cytologically and/or
histologically positive BM instead of 5%).
Another major clinical application for MRI and immuno-
staining could be the follow-up of BM metastases shown by
MRI after chemotherapy to better evaluate the response to
a
therapy which is known to be a major prognostic factor in
this disease.
This report is part of an ongoing study undertaken by our
institution in order to determine prospectively in a larger
series of patients the prognostic and therapeutic implications
of the use of these two complementary and non-aggressive
methods of tumour staging.
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Fuge 1 (a) Coronal TI-weighted MRI of patient no. 2 with BM involvement. Notice the well-circumscribed areas of low signal
intensity within the sacrum. (b) In the same patient, CT scan does not demonstrate any evidence of bone abnormalities.BONE MARROW METASTASES 87
Figure 2 In this patient (no. 3). TI-weighted spin-echo image demonstrates major BM involvement: all lumbar vertebral bodies
and the upper extremities of both femoral heads present diffuse areas of heterogeneous low intensity signals.
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